Clinical Trial Update: A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating CEND-1 in combination with chemotherapy as first-line therapy for pancreatic ductal adenocarcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• CEND-1

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 2 | Status: RECRUITING